Marko Mrkobrada

P.J. Devereaux, M .D., Ph.D., Marko Mrkobrada, M.D., Daniel I. Sessler, M.D., Kate Leslie, M.B., B.S., M.D., M.Epi., Pablo Alonso-Coello, M.D., Ph.D., Andrea Kurz, M.D., Juan Carlos Villar, M.D., Ph.D., Alben Sigamani, M.B., B.S., M.D., Bruce M. Biccard, M.B., Ch.B., Ph.D., Christian S. Meyhoff, M.D., Ph.D., Joel L. Parlow, M.D., Gordon Guyatt, M.D., Andrea Robinson, B.Sc., Amit X. Garg, M.D., Ph.D., Reitze N. Rodseth, M.B., Ch.B., Ph.D., Fernando Botto, M.D., Giovanna Lurati Buse, M.D., Denis Xavier, M.D., Matthew T.V. Chan, M.B., B.S., Maria Tiboni, M.D., Deborah Cook, M.D., Priya A. Kumar, M.D., Patrice Neglect, M.D., Ph.D., German Malaga, M.D., Edith Fleischmann, M.D., Mohammed Amir, F.R.C.S.Ed., John Eikelboom, M.B., B.S., Richard Mizera, M.D., David Torres, M.D., C.Y.

Current standard-of-care therapies for CMV disease have toxic effects which prevent their use both before engraftment and prophylactically. Myelosuppression, which is specially critical in recipients of allogeneic hematopoietic-cell transplants, prospects to elevated susceptibility to secondary infections. In this study of letermovir, the incidence of neutropenia was nearly similar in the letermovir and placebo groupings . These findings contrast with reported incidences of neutropenia of up to 58 percent with valganciclovir or more to 26 percent with CMX001.14-17 However, our study included a relatively few patients and did not enable comparisons of long-term survival outcomes.